Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Galera Therapeutics, Inc. (GRTX : NSDQ)

• Company Description    Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel, proprietary therapeutics to transform radiotherapy in cancer. The company's product candidate is GC4419, a highly selective and potent small molecule dismutase mimetic which is designed to rapidly convert superoxide to hydrogen peroxide. Galera Therapeutics, Inc. is headquartered in Malvern, PA. Number of Employees: 30

• Price / Volume Information    Yesterday's Closing Price: $1.67 Daily Weekly Monthly 20 Day Moving Average: 211,813 shares Shares Outstanding: 26.82 (millions) Market Capitalization: $44.79 (millions) Beta: 2.40 52 Week High: $10.79 52 Week Low: $1.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.36% -3.55% 12 Week -25.11% -17.68% Year To Date -63.62% -52.88%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 WEST LIBERTY BOULEVARD SUITE 100 - MALVERN,PA 19355 USA ph: 610-725-1500 fax: - help@astfinancial.com http://www.galeratx.com

• General Corporate Information    Officers J. Mel Sorensen - Chief Executive Officer; President and Director Michael Powell - Chairman Christopher Degnan - Chief Financial Officer Lawrence Alleva - Director Emmett Cunningham - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 36338D108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 26.82 Most Recent Split Date: (:1) Beta: 2.40 Market Capitalization: $44.79 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.46 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.36 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 45.68% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 22.67% vs. Previous Quarter: 9.38% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - -83.88 12/31/21 - -87.58 09/30/21 - -90.93 Current Ratio 03/31/22 - 5.97 12/31/21 - 5.98 09/30/21 - 5.89 Quick Ratio 03/31/22 - - 12/31/21 - 5.98 09/30/21 - 5.89 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - -2.63 12/31/21 - -2.19 09/30/21 - -1.64 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©